MYGN "Judge Invalidates Human Gene Patent" for BRCA1/BRCA2
This destroys MYGN's business model and takes away incentives for companies to develop diagnostics useful for personalized medicine. Back to "one size fits all" medication if you can't tell who gets the most benefit or harm from a particular drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.